We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine kinase inhibitor) in chronic myeloid leukemia (CML) expected in early...
FOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
FOSTER CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
FOSTER CITY, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.69 | -10.599078341 | 6.51 | 6.51 | 5.46 | 1675820 | 5.82854975 | CS |
4 | -0.95 | -14.0324963072 | 6.77 | 7.6299 | 5.46 | 1370620 | 6.60691314 | CS |
12 | -1.93 | -24.9032258065 | 7.75 | 11.4 | 5.46 | 2096893 | 8.55461906 | CS |
26 | -0.3 | -4.90196078431 | 6.12 | 11.4 | 5.46 | 1595782 | 8.18819585 | CS |
52 | 1.88 | 47.7157360406 | 3.94 | 11.4 | 3.59 | 1193893 | 7.58241905 | CS |
156 | -2.66 | -31.3679245283 | 8.48 | 14.0435 | 1.45 | 637071 | 7.48212537 | CS |
260 | -11.13 | -65.6637168142 | 16.95 | 28.36 | 1.45 | 524606 | 7.90970991 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions